Literature DB >> 30393600

Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

Niki Karachaliou1,2, Manuel Fernandez-Bruno1, Rafael Rosell2,3,4,5.   

Abstract

Entities:  

Year:  2018        PMID: 30393600      PMCID: PMC6193917          DOI: 10.21037/tlcr.2018.07.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  22 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells.

Authors:  Debangshu Samanta; Youngrok Park; Xuhao Ni; Huili Li; Cynthia A Zahnow; Edward Gabrielson; Fan Pan; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-24       Impact factor: 11.205

3.  Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy.

Authors:  Brian M Alexander; Jonathan D Schoenfeld; Lorenzo Trippa
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

Review 4.  Treatment of Advanced Non-Small Cell Lung Cancer in 2018.

Authors:  Deborah B Doroshow; Roy S Herbst
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

5.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

10.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

View more
  4 in total

Review 1.  Epidrugs: targeting epigenetic marks in cancer treatment.

Authors:  Cristiana Libardi Miranda Furtado; Maria Claudia Dos Santos Luciano; Renan Da Silva Santos; Gilvan Pessoa Furtado; Manoel Odorico Moraes; Claudia Pessoa
Journal:  Epigenetics       Date:  2019-07-13       Impact factor: 4.528

Review 2.  Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms.

Authors:  Mihailo Miljanic; Anna Capasso; Todd A Triplett; S Gail Eckhardt; Kyaw L Aung
Journal:  J Immunother Precis Oncol       Date:  2020-02-10

3.  Determination of a prediction model for therapeutic response and prognosis based on chemokine signaling-related genes in stage I-III lung squamous cell carcinoma.

Authors:  Jinzhi Lai; Shiyu Yang; Shuqiang Chu; Tianwen Xu; Jingshan Huang
Journal:  Front Genet       Date:  2022-08-31       Impact factor: 4.772

4.  A proteogenomic portrait of lung squamous cell carcinoma.

Authors:  Shankha Satpathy; Karsten Krug; Pierre M Jean Beltran; Sara R Savage; Francesca Petralia; Chandan Kumar-Sinha; Yongchao Dou; Boris Reva; M Harry Kane; Shayan C Avanessian; Suhas V Vasaikar; Azra Krek; Jonathan T Lei; Eric J Jaehnig; Tatiana Omelchenko; Yifat Geffen; Erik J Bergstrom; Vasileios Stathias; Karen E Christianson; David I Heiman; Marcin P Cieslik; Song Cao; Xiaoyu Song; Jiayi Ji; Wenke Liu; Kai Li; Bo Wen; Yize Li; Zeynep H Gümüş; Myvizhi Esai Selvan; Rama Soundararajan; Tanvi H Visal; Maria G Raso; Edwin Roger Parra; Özgün Babur; Pankaj Vats; Shankara Anand; Tobias Schraink; MacIntosh Cornwell; Fernanda Martins Rodrigues; Houxiang Zhu; Chia-Kuei Mo; Yuping Zhang; Felipe da Veiga Leprevost; Chen Huang; Arul M Chinnaiyan; Matthew A Wyczalkowski; Gilbert S Omenn; Chelsea J Newton; Stephan Schurer; Kelly V Ruggles; David Fenyö; Scott D Jewell; Mathangi Thiagarajan; Mehdi Mesri; Henry Rodriguez; Sendurai A Mani; Namrata D Udeshi; Gad Getz; James Suh; Qing Kay Li; Galen Hostetter; Paul K Paik; Saravana M Dhanasekaran; Ramaswamy Govindan; Li Ding; Ana I Robles; Karl R Clauser; Alexey I Nesvizhskii; Pei Wang; Steven A Carr; Bing Zhang; D R Mani; Michael A Gillette
Journal:  Cell       Date:  2021-08-05       Impact factor: 66.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.